FeesSafety
Pluang+

Phoenix Education Partners downgraded to Hold on weak 2027 outlook and AI challenges.

Analyst Insights
06 Nov 2026, 15:50 WIB
Seeking Alpha
View Source
Bearish
Phoenix Education Partners downgraded to Hold on weak 2027 outlook and AI challenges.

Phoenix Education Partners has been downgraded to a 'Hold' rating due to weak guidance for fiscal year 2027 and ongoing challenges from AI impacting consumer enrollment. The company trades at a low multiple of about 2.3 times forward EBITDA, but its adjusted EBITDA is expected to decline by 3.6–9.6% to $225–$240 million, with revenue forecasted to remain flat around $970 million to $1 billion. While there is potential upside if the stock re-rates to 3–4 times EBITDA, uncertainty remains due to operational challenges and investor concerns related to Apollo's involvement.

Phoenix Education stock is the subject, with this market snapshot from Pluang as of Nov 06, 2026 20:41 WIB: Among 134 Consumer Cyclical-sector US stocks priced on Pluang, 40 rose and 90 fell today. Airbnb (ABNB) gained 14.03% to USD 194.00 with a typical hold time of 141 days and 94% buy order activity. Plby Group Inc (PLBY) rose 10.48% to USD 1.37 but had 100% sell order activity, while Under Armour Inc Class A (UA) dropped 9.95% to USD 4.84 with a typical hold time of 22 days.

More News

BriaCell and BriaPro reveal promising preclinical immunotherapy data at SITC 2026.

BriaCell and BriaPro reveal promising preclinical immunotherapy data at SITC 2026.

BriaCell Therapeutics and its subsidiary BriaPro presented positive preclinical data at the SITC 2026 Annual Meeting, highlighting their immunotherapy platforms Bria-OTS+ and BP-80. Bria-OTS+ showed broad immune activation and sustained cancer cell k...

Others
Bullish
13 minutes ago
IMUNON's IMNN-001 boosts anti-tumor T-cell activity, improving survival in advanced ovarian cancer Phase 2 trial.

IMUNON's IMNN-001 boosts anti-tumor T-cell activity, improving survival in advanced ovarian cancer Phase 2 trial.

IMUNON, Inc. presented new data from its Phase 2 OVATION 2 trial showing that IMNN-001, combined with chemotherapy, significantly enhances anti-tumor T-cell immune responses in advanced ovarian cancer patients. This immune activation correlates with ...

Market News
Bullish
13 minutes ago
Minerva Neurosciences reports Q3 2026 results; Phase 3 trial of roluperidone for schizophrenia negative symptoms ongoing.

Minerva Neurosciences reports Q3 2026 results; Phase 3 trial of roluperidone for schizophrenia negative symptoms ongoing.

Minerva Neurosciences announced its third quarter 2026 financial results and business updates, highlighting progress in its Phase 3 trial of roluperidone, a drug targeting negative symptoms of schizophrenia. The ongoing C19 study aims to confirm prio...

Company Fundamentals
Bullish
13 minutes ago
Nexans to supply 420 km cable for Greece's major 1 GW Corinth-Kos power link

Nexans to supply 420 km cable for Greece's major 1 GW Corinth-Kos power link

Nexans has signed a subcontract to deliver a 420 km mass-impregnated 110 kV cable system for the 1 GW, 320 kV Corinth-Kos HVDC interconnection in Greece. This project, awarded to Hellenic Cables and partners, will connect the Dodecanese islands to ma...

Market News
Bullish
2 hours ago
Guggenheim raises JFrog price target to $125 after strong Q3 earnings and cloud revenue growth

Guggenheim raises JFrog price target to $125 after strong Q3 earnings and cloud revenue growth

Guggenheim analyst Howard Ma raised JFrog's price target to $125, signaling a 67.5% potential upside from its current price of $74.62. JFrog reported strong Q3 2026 results with revenue up 31% year-over-year to $179.2 million, driven by a 60% surge i...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App